Serum anti-phenolic glycolipid1 IgA correlates to IgM isotype in leprosy patients: a possible candidate for seroepidemiological surveys? by Macedo, Alexandre C. de et al.
J Clin Lab Anal. 2018;32:e22276.	 wileyonlinelibrary.com/journal/jcla	 	 | 	1 of 7
https://doi.org/10.1002/jcla.22276
© 2017 Wiley Periodicals, Inc.
Received:	3	June	2016  |  Accepted:	11	May	2017
DOI: 10.1002/jcla.22276
R E S E A R C H  A R T I C L E
Serum anti- phenolic glycolipid—1 IgA correlates to IgM 
isotype in leprosy patients: a possible candidate for 
seroepidemiological surveys?
Alexandre C. de Macedo1 | Juliana A. Guimarães1 | Raphael O. Rodrigues1 |  
Thiago D. V. Araújo2 | Clodis M. Tavares3 | Paula B. Cabral4 |  
Maria Isabel de Moraes-Pinto5 | Aparecida T. Nagao-Dias1
1Department	of	Clinical	Analysis	and	
Toxicology, Faculty of Pharmacy, Universidade 
Federal do Ceará- UFC, Fortaleza, Brazil
2Department of Pharmacy, Faculty of 
Pharmacy, UFC, Fortaleza, Brazil
3School of Nursery and Pharmacy 
(ESENFAR),	Universidade	Federal	de	Alagoas,	
Maceió,	Brazil
4Division of Pharmacy, Hospital Universitário 
Walter Cantídio, Universidade Federal do 
Ceara, Fortaleza, Brazil
5Division of Pediatric Infectious 
Diseases, Universidade Federal de Sao Paulo, 
Sao Paulo, Brazil
Correspondence
Prof.	Aparecida	Tiemi	Nagao	Dias,	Laboratory	
of Immunology, Department of Clinical 
Analysis	and	Toxicology,	Faculty	of	Pharmacy,	
Universidade Federal do Ceará, Fortaleza, 
Ceara, Brazil.
Email: tiemindi@yahoo.com.br
Funding information
MCTI/CNPq/MS-SCTIE,	Grant/Award	
Number: process 403461/2012-0
Objective: The	aim	of	this	study	was	to	compare	serum	anti-	phenolic	glycolipid-	1	IgA,	
IgG,	and	IgM	levels	in	leprosy	patients	and	controls.
Method: Analysis	of	anti-	PGL-	1	IgA,	IgG,	or	IgM	in	serum	samples	from	multibacillary	
(MB,	n=32)	and	paucibacillary	(PB,	n=22)	leprosy	patients,	and	in	non-	endemic	con-
trols	(n=17),	using	an	indirect	enzyme-	linked	immunosorbent	assay.
Results: A	strong	correlation	between	serum	IgM	and	IgA	isotypes	was	found	(r=.745,	
P<.0001)	in	MB	patients.	A	moderate	correlation	was	found	in	all	analyses	in	PB	pa-
tients.	A	moderate	agreement	was	found	between	anti-	PGL1	IgA	and	IgM	tests.	Based	
on the ROC curves, the cut- off values were selected and the parameters of validation 
were calculated. Considering the clinical forms altogether, the diagnostic sensitivities 
were	50.0%	for	IgA,	22.2%	for	IgG,	and	74.1%	for	IgM.	The	positive	(VPP)	and	nega-
tive	 (VPN)	predictive	values	were	estimated	for	each	 isotype.	For	 IgA,	the	VPP	and	
VPN	were,	respectively,	100.0%	(87.0%-	100.0%;	95%	confidence	interval)	and	38.7%	
(24.4%-	54.5%);	 for	 IgG,	 100%	 (87.0%-	100.0%)	 and	 28.8%	 (17.8%-	42.1%),	 respec-
tively;	and	for	IgM,	95.2%	(83.8%-	99.4%)	and	51.7%	(32.5%-	70.6%),	respectively.
Conclusion: Despite	the	limiting	factors,	anti-	PGL1	IgA	correlates	to	IgM	levels	and	it	
could be considered as a possible laboratorial tool to be also used, for instance, in 
 serological follow- up studies.
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1  | INTRODUCTION
Leprosy	 is	a	chronic	 infectious	disease	which	 is	 transmitted	through	
droplets from an index case presenting the multibacillary form of the 
disease to persons living in the same house or nearby1; nonetheless, 
it	 cannot	 be	 ruled	 out	 that	 skin	 lesions	 rich	 in	 viable	 bacilli	 might	
be potential sources of transmission.2 Brazil comprises the group 
of	14	 countries	 responsible	 for	95%	of	new	cases	of	 leprosy	 in	 the	
world.3 The overall detection rate of cases in Brazil was 14.06 cases 
per 100 000 inhabitants in 2015.4	 The	North	 and	Midwest	 regions	
presented	the	highest	 incidence	of	 leprosy,	that	 is,	29.59	and	36.69	
new cases per 100 000 inhabitants, respectively, in that same year.4 
The Northeastern Region showed an overall detection rate of 22.71 
cases per 100 000 inhabitants.4	 In	Alagoas	 (which	 is	 situated	 in	 the	
Northeastern	 Region),	 the	 Secretariat	 of	 Health	 reported	 that	 Rio	
Largo	 and	 Santana	 do	 Ipanema	 presented	 an	 overall	 detection	 rate	
of	 19.82	 and	 39.79	 cases	 per	 100	000	 inhabitants,	 respectively,	 in	
2015.4	Another	 important	parameter	 in	 the	epidemiology	of	 leprosy	
concerns to the case detection rate among children under 15 years 
of age, once it is probably related to recent infection and active focus 
2 of 7  |     de MACedO et Al.
of transmission in the community.5	The	Northern,	Midwestern,	 and	
Northeastern	regions	also	presented	the	highest	 frequencies	of	 lep-
rosy	cases	among	children	under	15	years	of	age,	that	is,	9.62,	7.89,	
and 7.46 cases per 100 000 individuals.4 The diagnosis of leprosy is 
essentially based on clinical and epidemiological studies. Considering 
the mode of transmission, contacts from non- treated multibacillary 
leprosy patients, are more prone to develop the disease than the 
general population.6,7 One of the major challenges in leprosy is the 
disease	diagnosis	which	 is	based	mostly	on	the	professional	skills	 in	
searching	for	skin	lesions	and	peripheral	nerve	alteration.	Skin	smears	
are	neither	often	positive	nor	the	serology.	Although	serology	is	not	
used in routine, it has been widely explored in research studies since 
the	discovery	of	the	phenolic	glycolipid	antigen	1	(PGL	1),	a	molecule	
specific of Mycobacterium leprae.8,9	Enzyme-	linked	immunosorbent	as-
says	(ELISA)	for	the	detection	of	anti-	PGL	1	IgM	antibodies	in	serum	
have shown high diagnostic sensitivity mostly for the multibacillary 
form of the disease.10,11 Based on the fact that phenolic glycolipid an-
tigen	is	a	T-	independent	antigen,	the	IgM	isotype	against	PGL-	1	is	the	
only	isotype	most	frequently	searched	in	serum	samples	from	patients	
and contacts.12,13	Although	the	test	for	anti-	PGL1	serum	IgG	presents	
a high diagnostic specificity,14	 it	 lacks	 diagnostic	 sensitivity.15	 Very	
few	reports	were	found	concerning	serum	anti-	PGL1	IgA	isotype.16,17 
According	to	these	authors,	the	subclass	antibody	anti-	PGL1	IgA1	was	
correlated with the bacterial index in leprosy.
The	 importance	of	 IgA	 for	mucosal	host	 immunity	 is	well	 estab-
lished18-20;	however,	knowledge	about	its	protective	role	in	systemic	
circulation is still doubtful.21 Nonetheless, in the last few years there 
has been increasing evidence of its usefulness for diagnosis of in-
fectious diseases, such as leptospirosis,22 toxoplasmosis,23 and den-
gue.24-26	The	IgA	isotype	presents	an	advantage	in	comparison	to	the	
IgM	and	IgG	isotypes	because	it	appears	early	in	infection	and	disap-
pears much faster than them.26	Thus,	the	purpose	of	the	present	work	
was	to	compare	serum	anti-	PGL1	IgA,	 IgG	and	IgM	levels	 in	 leprosy	
patients and controls.
2  | MATERIALS AND METHODS
2.1 | Controls and leprosy patients
The	leprosy	patients	(n=54)	were	divided	according	to	the	WHO	op-
erational classification,27	that	is,	up	to	five	skin	lesions	(paucibacillary	
form)	and	more	than	five	skin	lesions	(multibacillary	form).	Blood	sam-
ples	were	collected	from	32	multibacillary	(MB)	patients	(14	females	
and	17	males,	age	range	of	10-	80	years	old;	median	46	years	old)	and	
22	paucibacillary	(PB)	patients	(15	females	and	7	males,	age	range	of	
15-	69	years	old;	median	44	years	old)	living	in	the	cities	of	Santana	do	
Ipanema	and	Rio	Largo,	Alagoas	state,	Brazil,	or	in	the	cities	of	Crato	
and	Maracanaú,	Ceará	State,	Brazil.
The patients were selected according to the registration at the 
National	Notifiable	Diseases	System	(SINAN)	by	the	Municipal	Health	
Secretariat. The patients were invited to go to the municipal health 
centers where the project was explained, and, after informed consent, 
a	questionnaire	was	applied.
Seventeen individuals (who reported no contact with leprosy 
	patients)	living	in	São	Paulo	city	which	presents	a	low	incidence	of	lep-
rosy	(1.47	cases	per	100	000	inhabitants),4 were also included in the 
project	for	serological	evaluation	(control	group	-	CT	group).
The study was approved by the Ethics Committee of Universidade 
Federal	do	Ceará,	and	each	participant	or	his/her	guardian	was	asked	
to sign a written informed consent.
2.2 | Samples
Five milliliters of venous blood were collected into clot activator tubes 
containing	gel	separator.	After	30	minutes,	 the	samples	were	centri-
fuged at 1500× g for 10 minutes, and the serum was separated and 
stored	at	−20°C.
2.3 | Serum antibody titers
Serological	analyses	for	anti-	PGL1	antibodies	were	performed	accord-
ing to the procedure described elsewhere,28 with some modifications. 
Ninety-	six	well	flat-	bottom	microplates	(code	3590,	Costar,	USA)	were	
coated	with	5	mg/L	of	native	PGL-	1	in	absolute	ethyl	alcohol	(50	μL	per	
well),	kindly	donated	by	the	Bei	Resources/ATCC	(Manassas,	USA).	The	
plates	were	left	uncovered	for	2	hour	at	37°C.	After,	they	were	incu-
bated	with	1%	inactivated	fetal	bovine	serum	(FBS;	LGC	Bio,	Brazil)	in	
phosphate-	buffered	saline	(PBS,	pH	7.4)	for	2	hour	at	37°C in a humid 
chamber.	After	five	washes	with	PBS-	0.05%	FBS,	serum	samples	previ-
ously	diluted	(1:200	for	IgG	and	IgM	and	1:50	for	IgA)	in	PBS-	1%	FBS	
were added to the plates (50 μL	per	well,	in	duplicate).	The	plates	were	
then incubated for 2 hour at 37°C.	After	washing,	peroxidase-	labeled	
anti-	IgG	(A0170,	Sigma,	USA)	anti-	IgM	(SAB3701404,	Sigma,	USA)	or	
anti-	IgA	 (A0295,	 Sigma,	 USA),	 previously	 diluted	 to	 1:2500,	 1:9000,	
1:1000	(respectively)	was	added	to	the	plates	and	incubated	for	1.5	hour	
at 37°C.	After	washing,	the	plates	were	incubated	for	30	minutes	with	
the substrate solution (100 μL	per	well)	which	contained	0.4	mg	ortho-
phenylenediamine/mL	of	0.01	mol	L−1 citrate- phosphate buffer, pH 5.0 
and 0.01% H2O2 final concentration. The reaction was interrupted by 
adding 25 μL	2.5	N	sulfuric	acid.	The	analysis	was	performed	at	492	nm	
using	 an	ELISA	plate	 reader	 (ASYS	Expert	Plus,	Biochrom,	UK).	 Fifty	
serum samples from blood donors were pooled and used as cut- off 
sample in all assays. Negative and positive controls were included in 
each	assay.	The	cut-	off	sample	and	controls	were	run	in	quadruplicate.
The results were expressed in indices according to the following for-
mula:	optical	density	(OD)	mean	of	the	test	sample	(minus	blank)	divided	
by	the	OD	mean	of	the	normal	human	serum	pool	(minus	blank).28 Blood 
donors	were	seronegative	donors	to	HIV,	Chagas,	hepatitis	B	and	C,	HTLV,	
syphilis and that did not have leprosy at the time of sample collection.
2.4 | Statistical analysis
The data were analyzed using non- parametric tests once the data did 
not	 follow	 a	 Gaussian	 distribution	 (Kolgomorov-	Smirnov	 test).	 The	
Kruskall-	Wallis	 and	 the	 Dunn′s	 tests	 were	 used	 to	 compare	 values	
among three or more unpaired groups. Paired data were analyzed by 
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the Spearman correlation test. The analyses were performed using the 
GraphPad	Prism	version	5.0	and	the	GraphPad	Instat	version	3.01	pro-
grams.	The	level	of	statistical	significance	was	considered	to	be	equal	to	
or less than .05. The Spearman coefficients were also used to assess the 
degree of correlation between the tests. The values were interpreted as 
follows29: r=.10	to	.30	(weak);	r=.40	to	.6	(moderate);	r=.70	to	1	(strong).	
Diagnostic sensitivity and specificity, positive and negative predictive 
values, and the receiver operating characteristic curves were obtained 
by	the	GraphPad	Prism	version	5.0.	The	Kappa	index	(k)	was	applied	to	
evaluate	the	degree	of	agreement	between	the	results	obtained.	Kappa	
values	can	be	interpreted	as	follows:	0,	no	agreement;	0	to	0.19,	low	
concordance;	 0.20	 to	 0.39,	 fair	 agreement;	 0.40	 to	 0.59,	 moderate;	
0.60	to	0.79	substantial,	0.80-	1.00,	almost	perfect	agreement.30
3  | RESULTS
3.1 | Serum anti- PGL1 antibodies in controls and 
leprosy patients
The	patients	with	the	multibacillary	form	of	the	disease	(MB)	showed	
much	 higher	 anti-	PGL1	 IgM	 titers	 than	 controls	 (P<.0001).	 Similar	
	observations	were	done	for	the	IgG	isotype	(P<.05).	For	the	anti-	PGL1	
IgA	isotype,	the	PB	and	MB	patients	presented	higher	levels	than	the	
controls (P<.05 and P<.01),	respectively	(Figure	1).
3.2 | Correlation between serum anti- PGL1 
antibody titers
A	 weak	 correlation	 was	 found	 between	 serum	 IgG	 and	 IgA	 iso-
types	among	the	MB	patients	 (Spearman	correlation,	 r=.363;	P=.04,	
Figure	2A);	 a	 moderate	 correlation	 was	 found	 between	 serum	 IgM	
F IGURE  1 Titers	of	serum	anti-	PGL1	IgM,	IgG,	and	IgA	in	non-	
endemic	controls	(CT,	n=17),	and	in	paucibacillary	(PB,	n=22)	and	
multibacillary	(MB,	n=32)	leprosy	patients
F IGURE  2 Correlation	between	serum	anti-	PGL1	IgG,	IgA,	and	IgM	in	multibacillary	leprosy	patients
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and	IgG	isotypes	(r=.479,	P=.0055,	Figure	2B),	and	a	strong	correlation	
was	 found	 between	 serum	 IgM	 and	 IgA	 isotypes	 (r=.745,	P<.0001, 
Figure	2C).	In	respect	to	the	PB	patients	(n=22),	a	moderate	correla-
tion	was	 found	 in	 all	 analyses,	 that	 is,	 between	 serum	 IgG	 and	 IgA	
isotypes (r=.509;	P=.015,	Figure	3A),	between	serum	IgM	and	IgG	iso-
types (r=.645,	P=.0012,	Figure	3B),	and	between	serum	IgM	and	IgA	
isotypes (r=.595,	P=.0035,	Figure	3C).
3.3 | Receiver operating characteristic (ROC) curves, 
diagnostic sensitivities and specificities, negative and 
positive predictive values
Data from patients and controls were used to build the ROC curves, as 
represented	in	Figures	4A-	C.	Based	on	the	ROC	curves,	it	was	possi-
ble	to	select	the	cut-	off	values,	that	is,	1.1	for	IgA,	1.2	for	IgM	and	IgG	
tests.	After	selection	of	the	cut-	off	points,	the	following	parameters	
were	calculated:	The	diagnostic	sensitivities	for	serum	anti-	PGL1	IgA,	
IgG,	and	IgM	in	PB	patients	were	40.9%,	22.7%,	and	59.1%,	respec-
tively,	 and	 53.1%,	 21.9%,	 and	 81.3%	 for	 the	 same	 isotypes	 in	MB	
patients	 (Table	1).	 The	 diagnostic	 specificities	were	 100.0%	 for	 the	
IgA	and	IgG	isotypes,	and	88.2%	for	the	IgM	isotype.	Considering	the	
clinical forms altogether, the diagnostic sensitivities were 50.0% for 
IgA,	22.2%	for	IgG	and	74.1%	for	IgM.	The	positive	(VPP)	and	nega-
tive	(VPN)	predictive	values	were	estimated	for	each	isotype.	For	IgA,	
the	VPP	and	VPN	were,	 respectively,	 100.0%	 (87.0%-	100.0%;	95%	
confidence	interval)	and	38.7%	(24.4%-	54.5%);	for	IgG,	100%	(87.0%-	
100.0%)	and	28.8%	(17.8%-	42.1%),	respectively;	and	for	IgM,	95.2%	
(83.8%-	99.4%)	and	51.7%	(32.5%-	70.6%),	respectively.
3.4 | Assessment of the degree of agreement 
between serum anti- PGL1 IgM and anti- PGL1 
IgA tests
Serum	 samples	 from	 the	 leprosy	 patients	 (n=54)	 were	 tested	 for	
agreement	between	anti-	PGL1	IgA	and	IgM	tests.	The	Table	2	shows	
the	frequency	of	positive	and	negative	titers	 for	both	 isotypes.	The	
index	Kappa	was	0.48,	calculated	according	to	described	elsewhere,30 
and presented a moderate agreement.
4  | DISCUSSION
The high number of new cases of leprosy reported every year in Brazil 
reveals that the control of the disease is far from being achieved. 
F IGURE  3 Correlation	between	serum	anti-	PGL1	IgG,	IgA	and	IgM	in	paucibacillary	leprosy	patients
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Poor effective surveillance system, very few laboratory diagnostic 
tools,	skin	smears	done	without	quality	assurance,31 professionals not 
skilled	in	making	early	diagnosis	5 are some of the factors that contrib-
ute	to	the	late	diagnosis	of	leprosy	and	consequently	poor	control	of	
the disease and its transmission. On this aspect, the huge challenge is 
to reduce transmission and to be able to identify those people who are 
prone	to	develop	the	disease.	For	this	reason,	search	for	biomarkers	is	
absolutely primordial.32
Few	considerations	must	be	done	about	the	technique.	We	have	
demonstrated recently 14 that 2 of 17 people who reported not to 
have contact with leprosy patients presented positive serum anti- 
PGL1	IgM	antibodies.	In	that	work,	we	have	found	a	high	frequency	
of	positive	anti-	PGL1	IgM	among	the	negative	anti-	PGL1	IgG	samples.	
The	question	 that	has	arisen	at	 that	 time	was	 in	 respect	 to	 the	 real	
meaning	of	seropositivity	of	anti-	PGL	1	IgM	antibodies.	False-	positive	
results are described in the literature in various circumstances. For 
example, rheumatoid factors may be produced in low amounts in in-
fectious diseases, such as toxoplasmosis,33 malaria,34 dengue,35 which 
lead	to	non-	specific	IgM	detection.	Some	authors	have	described	the	
existence of cross- reacting idiotypes, that is, specific antibodies that 
use the same antigenic site to interact with an unrelated epitope.36
In	 respect	 to	 the	PGL-	1	 antigen,	 as	 a	 glycophenolic	molecule,	 it	
is	at	 risk	of	being	affected	when	a	 long	period	of	 incubation	 is	per-
formed. For this reason, the adsorption incubation step was reduced 
to 2 hours at 37o C.
Another	 observation	 was	 related	 to	 the	 blocking	 step.	 Some	
 samples, especially those which contain high titers of antibodies, may 
present	 non-	specific	 reactivity	 to	 bovine	 serum	 albumin	 (BSA).	 For	
managing	such	circumstances,	various	concentrations	of	BSA	in	block-
ing solution were tested, but inhibition of nonspecific binding could 
not	be	completely	achieved.	Fetal	bovine	serum	(FBS)	showed	more	
confident	results	with	 lower	background	reaction,	besides	the	 lower	
price.
The cut- off value for each isotype was selected based on the ROC 
curves. Unfortunately, it was not possible to obtain very high diag-
nostic sensitivities.37 We speculate that for leprosy surveys, it is more 
important that the test presents a good specificity in spite of its sen-
sitivity. Our suggestion is based on the fact that leprosy contacts with 
abnormal	 levels	of	anti-	PGL1	shall	be	surveyed.	For	this	reason,	 it	 is	
rather	necessary	 that	 the	biomarker	bear	a	good	specificity	 in	order	
that it will provide a good positive predictive value. On the other hand, 
to compensate for the low negative predictive value it is useful to use 
two or more serological parameters.
As	it	has	been	shown	in	previous	studies,	lipid	antigen	may	elicit	
T- dependent humoral immune responses in case the bacteria are 
F IGURE  4  (A) Receiver operating characteristic curve for anti- 
PGL1	IgA.	Fifty-	four	serum	samples	from	leprosy	patients	were	
tested.	(B)	Receiver	operating	characteristic	curve	for	anti-	PGL1	
IgM.	Fifty-	four	serum	samples	from	leprosy	patients	were	tested.
(C)	Receiver	operating	characteristic	curve	for	anti-	PGL1	IgG.	 
Fifty- four serum samples from leprosy patients were tested
(A)
(B)
(C)
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ingested by phagocytes.38	As	the	presence	of	anti-	PGL1	IgG	has	been	
demonstrated in leprosy patients28 and in contacts,14 we have decided 
in	the	present	work	to	evaluate	anti-	PGL1	IgA	titers.
IgA	 is	being	considered	as	an	alternative	or	complementary	bio-
marker	 in	 the	diagnosis	of	some	pathologies.	For	 instance,	 it	 is	con-
sidered	 to	be	more	 sensitive	 than	 the	 IgM	 test	 for	 the	diagnosis	of	
congenital toxoplasmosis.39	IgA	is	also	considered	to	be	a	good	candi-
date for the diagnosis of acute dengue by the fact it remains shorter 
time	in	circulation	than	IgM	does.26	Finally,	in	the	decade	of	1990,	it	
has	been	suggested	that	IgA	could	be	used	in	early	stages	of	the	lep-
rosy disease and in subclinical infection.16,17
Our	current	data	demonstrated	a	better	performance	of	 the	 IgA	
than	the	IgG	isotype.	IgG	presented	a	moderate	correlation	with	IgM	
(r=.479,	P=.0055)	and	a	very	low	diagnostic	sensitivity	even	in	MB	pa-
tients.	On	the	other	hand,	IgA	showed	a	strong	correlation	with	IgM	
(r=.745,	P<.0001).	 Its	diagnosis	 sensitivity	 (53.1%)	was	much	higher	
than	that	of	IgG	(21.9%),	but	still	far	from	that	of	IgM	(81.3%)	in	MB	
patients.
The	moderate	Kappa	index	obtained	between	IgM	and	IgA	prob-
ably indicates how complex the immunological mechanisms are in 
leprosy disease. The complexity is not only restricted to the dichot-
omy cellular/humoral immune response but also in the humoral im-
mune	 repertoire.	The	PGL-	1	molecule	probably	behaves	as	 a	 “pure”	
T-	independent	 antigen	 in	 various	 patients,	 inducing	 solely	 the	 IgM	
isotype;	 nonetheless,	 in	 other	 patients,	 it	 behaves	 as	 a	 “partial”	 T-	
dependent	antigen,	also	inducing	IgG	and/or	IgA.
By	one	side,	a	question	remains	if	all	the	individuals	who	show	anti-	
PGL1	IgM	titers	can	be	considered	at	risk	of	developing	leprosy	disease	
once	the	frequency	of	positivity	is	high	among	household	contacts.14 
On the other hand, is it reasonable to expect that a contact who pres-
ents	positive	 IgA	 is	 really	at	high	 risk	of	developing	 the	disease.	For	
this reason, despite the mentioned limiting factors, we strongly rec-
ommend	that	IgA	be	considered	as	a	biomarker	adjuvant	to	IgM	to	be	
used in serological and clinical follow- up studies of household leprosy 
contacts in municipalities with high endemicity of the disease.
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